BARDA and Genentech collaborate to accelerate clinical trial of a novel COVID-19 therapeutic treatment

BARDA Response

BARDA expanded an existing partnership with Genentech, part of Roche Group and headquartered in South San Francisco, to accelerate a Phase 3 clinical trial of Actemra® (tocilizumab) as a potential treatment of patients with severe cases of COVID-19. Currently, Actemra® is approved by the U.S. Food and Drug Administration and in more than 100 countries to treat rheumatoid arthritis or other inflammatory conditions.

Patients with COVID-19 are at risk of developing life-threatening respiratory failure, which may be mediated in part by elevated levels of a series of pro-inflammatory molecules, including interleukin-6 (IL-6). Actemra ® is a monoclonal antibody that binds to the IL-6 receptor on normal cells and may improve patient outcomes by decreasing the severe inflammatory response.

Therapeutic treatments, antiviral drugs and vaccines are critical in combating 2019 novel coronavirus infections (COVID-19). BARDA is providing $25 million toward the clinical trial to determine if Actemra ® can reduce the duration of severe illness and hospitalization in a person infected with the novel coronavirus . If found to be safe and effective by the FDA, the therapeutic could be used in conjunction with future COVID-19-specific antiviral therapeutics.

This award is one component of BARDA’s Rapidly-Expanding COVID-19 Medical countermeasure portfolio, visit BARDA’s COVID-19 Portfolio to learn more.

About Genentech:

The following information is provided by the company and does not indicate endorsement by the federal government of the company or its products.

Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. Genentech, a member of the Roche Group, has headquarters in South San Francisco, California. 

Website Refresh - is pleased to announce a phased launch of our newly redesigned public website. We are making website improvements to provide a more modern and customer-centric web experience. Over the next several months you will see differences throughout the site while we continue implementing updates. Thank you for your understanding and please let us know if you have any questions: